Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Alcohol Clin Exp Res ; 36(1): 72-82, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21762182

ABSTRACT

BACKGROUND: Fetal alcohol spectrum disorder (FASD) is often accompanied by reduced brain volumes, reflecting brain cell death induced by ethanol, but the molecular mechanisms were less elucidated. This study was set up to investigate whether clusterin (Clu) was involved in neuronal cell death in developing rats. METHODS: Seven-day-old rats were subcutaneously injected with 20% ethanol in normal saline at 3 g/kg twice. The upregulation of Clu and cell death was detected by immunohistochemistry, immunofluorescence microscopy, and/or Western blotting. Protein-protein interaction was detected by immunoprecipitation and immunoblotting. To identify the isoform interacting with Bcl-XL, HT22 mouse hippocampal cells were transfected with nuclear Clu(nClu)- or secretory Clu-expressing vector, and confocal microscopy was performed. Clu transcripts were knocked down in primary cortical cells using siRNA. RESULTS: We found that Clu increased in the cerebral cortex following acute ethanol treatment. The Clu upregulation was related to increased cell death, which was assessed by activated caspase-3 and TUNEL staining. The upregulated Clu was a nuclear isoform that was nuclear translocated upon ethanol exposure and interacted with Bcl-XL, mediating apoptosis. CONCLUSIONS: This study shows that nClu plays a pro-apoptotic role in ethanol-induced cell death in the developing brain, providing new insights for development of FASD.


Subject(s)
Apoptosis/drug effects , Brain/growth & development , Brain/metabolism , Clusterin/metabolism , Ethanol/administration & dosage , Animals , Animals, Newborn , Brain/drug effects , Cell Nucleus/metabolism , Cell Survival/drug effects , Cells, Cultured , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Hippocampus/cytology , Mice , Rats , Rats, Sprague-Dawley , Up-Regulation
2.
Acta Ophthalmol ; 88(6): e217-21, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20560891

ABSTRACT

PURPOSE: The aim of the current study was to investigate the effects of triamcinolone acetonide (TA) upon the expression and phosphorylation of growth-associated protein 43 (GAP 43) in the retinas of oxygen-induced retinopathy (OIR) rats. METHODS: Oxygen-induced retinopathy was induced by exposing Sprague-Dawley rats to hyperoxia (80% oxygen) from postnatal (P) days 2-14 and then returning the rats to normoxic conditions. Triamcinolone acetonide or a conditioned saline (control) was injected intravitreally into the right or left eye, respectively, of OIR rats at P15. We then assessed the molecular and histological changes in the expression of GAP 43 and phospho-GAP 43 in OIR and control rat retinas, and also after treatment with TA by RT-PCR, Western blotting and immunohistochemistry. RESULTS: Growth-associated protein 43 mRNA levels were found to be increased by 1.6-fold (p=0.001, n=5) in the retinas of P18 OIR rats compared with the control rats. The protein levels of GAP 43 and phospho-GAP43 were found to be elevated in the retina of P18 OIR rats (2.40- and 2.39-fold greater than each control, p<0.001, n=5, respectively). Immunoreactivities of GAP 43 and phospho-GAP 43 were stronger in the inner plexiform layer in OIR rat retinas compared with the control. However, treatment with TA attenuated GAP 43 and phospho-GAP 43 upregulation in the OIR retinas. CONCLUSION: Our results indicate that GAP 43 and phospho-GAP 43 participate in retinal (potentially pathologic) changes following oxygen-induced damage. Triamcinolone acetonide protects the retinal damage in relatively hypoxic retinas of OIR rats. Therefore, TA treatment does not induce the expression and phosphorylation of GAP 43 in OIR rat retinas.


Subject(s)
Disease Models, Animal , GAP-43 Protein/genetics , GAP-43 Protein/metabolism , Gene Expression Regulation/drug effects , Glucocorticoids/pharmacology , Retinopathy of Prematurity/genetics , Triamcinolone Acetonide/pharmacology , Animals , Blotting, Western , Female , Humans , Hyperoxia , Immunohistochemistry , Infant, Newborn , Oxygen/toxicity , Phosphorylation , Pregnancy , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Retinopathy of Prematurity/metabolism , Retinopathy of Prematurity/pathology , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation
3.
J Neurosci ; 23(1): 230-9, 2003 Jan 01.
Article in English | MEDLINE | ID: mdl-12514220

ABSTRACT

The initiation of mammalian puberty requires the activation of hypothalamic neurons secreting the neuropeptide luteinizing hormone-releasing hormone (LHRH). It is thought that this activation is caused by changes in trans-synaptic input to LHRH neurons. More recently, it has been postulated that the pubertal increase in LHRH secretion in female animals also requires neuron-glia signaling mediated by growth factors of the epidermal growth factor (EGF) family and their astrocytic erbB receptors. Although it appears clear that functional astrocytic erbB1 receptors are necessary for the timely advent of puberty, the physiological contribution that erbB4 receptors may make to this process has not been established. To address this issue, we generated transgenic mice expressing a dominant-negative erbB4 receptor (DN-erbB4) under the control of the GFAP promoter, which targets transgene expression to astrocytes. DN-erbB4 expression is most abundant in hypothalamic astrocytes, where it blocks the ligand-dependent activation of glial erbB4 and erbB2 receptors, without affecting erbB1 (EGF) receptor signaling. Mice carrying the transgene exhibit delayed sexual maturation and a diminished reproductive capacity in early adulthood. These abnormalities are related to a deficiency in pituitary gonadotropin hormone secretion, caused by impaired release of LHRH, the hypothalamic neuropeptide that controls sexual development. In turn, the reduction in LHRH release is caused by the inability of hypothalamic astrocytes to respond to neuregulin (NRG) with production of prostaglandin E(2), which in wild-type animals mediates the stimulatory effect of astroglial erbB receptor activation on neuronal LHRH release. Thus, neuron-astroglia communication via NRG-erbB4/2 receptor signaling appears to be essential for the timely unfolding of the developmental program by which the brain controls mammalian sexual maturation.


Subject(s)
Astrocytes/physiology , ErbB Receptors/physiology , Hypothalamus/cytology , Neuregulins/physiology , Sexual Maturation , Animals , Astrocytes/metabolism , Cells, Cultured , Dinoprostone/metabolism , ErbB Receptors/genetics , Female , Fertility , Follicle Stimulating Hormone/metabolism , Glial Fibrillary Acidic Protein/genetics , Gonadotropin-Releasing Hormone/metabolism , Hypothalamus/physiology , Kinetics , Mice , Mice, Transgenic , Mutation , Neuregulins/pharmacology , Promoter Regions, Genetic , Receptor, ErbB-2/metabolism , Receptor, ErbB-4 , Sex Characteristics , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...